Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Edward M Kerwin, Lindsey Murray, Xiaoli Niu & Carole Dembek. (2020) Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2309-2318.
Read now
Read now
Konstantinos Kostikas, Alexander J Mackay, Claus F Vogelmeier, Stefan-Marian Frent, Pritam Gupta, Donald Banerji, Francesco Patalano, Pascal J Pfister & Jadwiga A Wedzicha. (2020) Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1831-1838.
Read now
Read now
Neil S. Skolnik, Trang Susan Nguyen, Aarisha Shrestha, Riju Ray, Thomas C. Corbridge & Stephen A. Brunton. (2020) Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgraduate Medicine 132:2, pages 198-205.
Read now
Read now
Arschang Valipour, Michael Tamm, Jana Kociánová, Valentina Bayer, Maria Sanzharovskaya, Alexey Medvedchikov, Monika Haaksma-Herczegh, János Mucsi, Zvi Fridlender, Claudia Toma, Andrey Belevskiy, Bohumil Matula & Jurij Šorli. (2019) Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2343-2354.
Read now
Read now
Dave Singh, Leonardo M Fabbri, Stefano Vezzoli, Stefano Petruzzelli & Alberto Papi. (2019) Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 531-546.
Read now
Read now
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, Maurice T Driessen, Nancy Risebrough, Andrew Briggs & Afisi S Ismaila. (2019) Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 939-951.
Read now
Read now
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier & Andreas Clemens. (2018) Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1229-1237.
Read now
Read now
Anthony D D’Urzo, Mario Cazzola, Nicola A Hanania, Roland Buhl & M Reza Maleki-Yazdi. (2018) New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2805-2819.
Read now
Read now
Articles from other publishers (26)
Wei-Chun Huang, Chih-Yu Chen, Wei-Chih Liao, Biing-Ru Wu, Wei-Chun Chen, Chih-Yen Tu, Chia-Hung Chen & Wen-Chien Cheng. (2022) Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Journal of Clinical Medicine 11:23, pages 7165.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. (2022) Clinically important deterioration: a composite tool for managing patients with COPD. Respiratory Medicine 205, pages 107054.
Crossref
Crossref
Hui-juan Shen, Jun-xia Jiang, Hong-yi Yao, Hai-yun Zhou, Qiang-min Xie, Hai-bin Dai & Xi-le Zhou. (2022) Glycopyrronium bromide regulates cigarette smoke-induced epithelial mesenchymal transition by mediating ACh production. Journal of Molecular Structure 1266, pages 133549.
Crossref
Crossref
Yuki Abe, Masaru Suzuki, Hironi Makita, Hirokazu Kimura, Kaoruko Shimizu, Satoshi Konno & Masaharu Nishimura. (2021) One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Qinxia Zhang, Haifu Zhang, Jianjun Wang, Zhaoyang Ruan, Yifan Dai, Zehai Xia & Qun Lv. (2021) Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis. Heart & Lung 50:4, pages 532-541.
Crossref
Crossref
Dave Singh, James F. Donohue, Isabelle H. Boucot, Neil C. Barnes, Chris Compton & Fernando J. Martinez. (2021)
Future concepts in bronchodilation for COPD: dual-
versus
monotherapy
. European Respiratory Review 30:160, pages 210023.
Crossref
Crossref
MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, Christine E. Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert A. Wise, Ian P. Naya & Dave Singh. (2021) Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research 7:1, pages 00663-2020.
Crossref
Crossref
Klaus F. Rabe, James D. Chalmers, Marc Miravitlles, Janwillem W. H. Kocks, Ioanna Tsiligianni, Alberto de la Hoz, Wenqiong Xue, Dave Singh, Gary T. Ferguson & Jadwiga Wedzicha. (2020) Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials. Advances in Therapy 38:1, pages 579-593.
Crossref
Crossref
Mona Bafadhel, Dave Singh, Christine Jenkins, Stefan Peterson, Thomas Bengtsson, Peter Wessman & Malin Fagerås. (2020) Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respiratory Research 21:1.
Crossref
Crossref
Klaus F. Rabe, David M. G. Halpin, MeiLan K. Han, Marc Miravitlles, Dave Singh, Lars Grönke, Florian Voß & Fernando J. Martinez. (2020) Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respiratory Research 21:1.
Crossref
Crossref
Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson & MeiLan K. Han. (2020) Measuring disease activity in COPD: is clinically important deterioration the answer?. Respiratory Research 21:1.
Crossref
Crossref
Vicente Benavides-Cordoba, Sebastian Aviles, Camila Ascuntar, Lina Orozco, Ricardo Mosquera & Julian Rivera. (2020) Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients. Pulmonary Pharmacology & Therapeutics 61, pages 101898.
Crossref
Crossref
S N Avdeev, Z R Aisanov, A S Belevsky, K M Beeh, A A Vizel, S K Zyryanov, G L Ignatova, K Kostikas, I V Leshchenko, S I Ovcharenko, A I Sinopal’nikov, O N Titova & E I Shmelev. (2020) The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy. Terapevticheskii arkhiv 92:1, pages 89-95.
Crossref
Crossref
Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes & François Maltais. (2020)
Impact of baseline COPD symptom severity on the benefit from dual
versus
mono-bronchodilators: an analysis of the EMAX randomised controlled trial
. Therapeutic Advances in Respiratory Disease 14, pages 175346662096850.
Crossref
Crossref
François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri & Claus F. Vogelmeier. (2019) Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research 20:1.
Crossref
Crossref
Brianna Atto, Mathew Suji Eapen, Pawan Sharma, Urs Frey, Alaina J. Ammit, James Markos, Collin Chia, Josie Larby, Greg Haug, Heinrich C. Weber, George Mabeza, Stephen Tristram, Stephen Myers, Dominic P. Geraghty, Katie L. Flanagan, Philip M. Hansbro & Sukhwinder Singh Sohal. (2019) New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clinical Science 133:14, pages 1663-1703.
Crossref
Crossref
Ian P. Naya, Lee Tombs, Hana Muellerova, Christopher Compton & Paul W. Jones. (2018) Long-term outcomes following first short-term clinically important deterioration in COPD. Respiratory Research 19:1.
Crossref
Crossref
Miriam Barrecheguren, Cruz González & Marc Miravitlles. (2018) What have we learned from observational studies and clinical trials of mild to moderate COPD?. Respiratory Research 19:1.
Crossref
Crossref
Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig, Francesco Patalano, Robert Fogel, Donald Banerji & Jadwiga A. Wedzicha. (2018) Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respiratory Research 19:1.
Crossref
Crossref
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa & Gregory Feldman. (2018) Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulmonary Therapy 4:2, pages 171-183.
Crossref
Crossref
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson & Gerard Criner. (2018) Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research 4:4, pages 00047-2018.
Crossref
Crossref
Ian P. Naya, Lee Tombs, David A. Lipson & Chris Compton. (2018) Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy 35:10, pages 1626-1638.
Crossref
Crossref
Anthony D’Urzo, Giovanni Bader, Steven Shen, Pankaj Goyal & Pablo Altman. (2018) Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. npj Primary Care Respiratory Medicine 28:1.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Gregory J. Feldman, Ana R. Sousa, David A. Lipson, Lee Tombs, Neil Barnes, John H. Riley, Sadhana Patel, Ian Naya, Chris Compton & Bernardino Alcázar Navarrete. (2017) Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Advances in Therapy 34:11, pages 2518-2533.
Crossref
Crossref
Mario Cazzola & Paola Rogliani. (2017) Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research 6:7, pages 627-636.
Crossref
Crossref